1.DETERMINATION OF TOTAL BODY FAT BY WATER DISPLACEMENT METHOD
Qing-Hui YANG ; Bing-Zhang DUAN ; Ya-Nan JIANG ;
Acta Nutrimenta Sinica 1956;0(02):-
Body fat of 12 male adults were measured by water displacement me-thod(density method) at every morning for 5 successive days. The standard deviation of single observation was 0.29kg calculated by mean residual lung volume method. It was significantly lower than the value (0.5kg) calculated by the ordinary method (p
2.The physiological effects of resveratrol and its potential application in high altitude medicine.
Hui-li ZHU ; Hong-jing NIE ; Pei-bing LI ; Bing-nan DENG ; Rui-feng DUAN ; Hong JIN ; Zhao-li CHEN
Chinese Journal of Applied Physiology 2015;31(6):498-503
Resveratrol, as a natural polyphenolic compound, has a wide range of beneficial effects, which includes anti-tumor, cardiovascular protection, anti-oxidant and estrogen-like effects, and so on. Its various physiological properties are closely related to the therapeutic principle for prevention and treatment of high altitude hypoxia injury. Resveratrol may play an important role in relieving or curing high altitude diseases, especially high altitude polycythemia(HAPC). However, the literature about study and application of resveratrol in plateau medicine field is rarely reported up to now. In this review, we summarized the physiological effects of resveratrol, discussed the possible main principle of resveratrol for HAPC therapy, and looked forward to resveratrol's perspective or potential application in high altitude medicine.
Altitude
;
Humans
;
Hypoxia
;
drug therapy
;
Polycythemia
;
drug therapy
;
Stilbenes
;
pharmacology
3.Effects of the new compound codonopsis tablets on brain performance capacity of youth at high altitude.
Hong-jing NIE ; Pei-bing LI ; Wei-gui YANG ; Bing-nan DENG ; Hui-li ZHU ; Li-xia YU ; Rui-feng DUAN ; Hai WANG ; Zhao-li CHEN
Chinese Journal of Applied Physiology 2015;31(2):114-116
Adolescent
;
Altitude
;
Brain
;
drug effects
;
Codonopsis
;
chemistry
;
Drugs, Chinese Herbal
;
pharmacology
;
Humans
;
Tablets
4.A rat model of high altitude polycythemia rapidly established by hypobaric hypoxia exposure.
Pei-Bing LI ; Hong-Jing NIE ; Wei LIU ; Bing-Nan DENG ; Hui-Li ZHU ; Rui-Feng DUAN ; Zhao-Li CHEN ; Hai WANG
Chinese Journal of Applied Physiology 2014;30(6):526-531
OBJECTIVETo investigate the effects of simple hypobaric hypoxia on parameters of hematology and blood rheology in order to establish a rat model of simulated high altitude polycythemia (HAPC) for the study of pathophysiologic mechanisms and medical prevention and treatment of HAPC.
METHODSForty-eight male Wistar rats were randomly divided into three normal control groups and three hypoxia model groups. Normal control group rats were bred in normoxia conditions, and hypoxia group rats were subjected to hypoxic exposure for 8 hours per day at simulated 5 500 m high altitude in a hypobaric chamber. After hypoxic exposure for 2, 4, 12 weeks, one group of normal control and hypoxia model rats were killed and blood was collected, respectively. Then parameters of erythrocyte and blood rheology were examined.
RESULTSMucous membrane of hypoxia model rats showed obviously cyanosis after 2 weeks hypoxic exposure. Hemoglobin concentration of hypoxia model rats were beyond 210 g/L after 2 weeks, 4 weeks and 12 weeks hypoxia exposure and significantly increased than that of normal control rats respectively. Besides, RBC counts, hematocrit, whole blood viscosity, erythrocyte aggregation index of hypoxia model rats were all notably higher than those of normal control rats respectively.
CONCLUSIONA rat model of high altitude polycythemia can be rapidly established by hypobaric hypoxia exposure at simulated 5 500 m high altitude for 8 hours daily.
Altitude ; Altitude Sickness ; Animals ; Disease Models, Animal ; Erythrocyte Count ; Hematocrit ; Hypoxia ; Male ; Polycythemia ; pathology ; Rats ; Rats, Wistar
5.Effects of oxygen supply unit for individual on HR and SaO2 at high altitude.
Bing-nan DENG ; Pei-bing LI ; Zhong MAO ; Hong-jing NIE ; Zhong-hai XIAO ; Hui-li ZHU ; Rui-feng DUAN ; Hai WANG ; Zhao-li CHEN
Chinese Journal of Applied Physiology 2015;31(1):17-22
Altitude
;
Heart Rate
;
Humans
;
Oxygen
;
Oxygen Consumption
6.Prediction of hemorrhagic transformation in acute ischemic stroke using permeability surface of CT perfusion
Bing XIONG ; Weijian CHEN ; Fengli FU ; Yuxia DUAN ; Boyang YANG ; Hongqing WANG ; Yunjun YANG ; Pan LIANG ; Yi LIN ; Shu WANG ; Nan WU ; Qiuyun TONG
Chinese Journal of Radiology 2012;46(7):593-597
Objective To investigate the value of permeability surface (PS) in predicting hemorrhagic transformation (HT) in acute ischernic stroke (AIS) using CT peffusion (CTP).Methods The study included 31 consecutive patients who presented symptoms suggestive of an AIS for 3-9 h. All patients underwent CT examination (noncontrast CT,CTP).HT was determined by follow-up CT images.According to presence of HT,the AIS was divided into HT group (PSHT,11 patients) and non-HT group(PSNo-HT,20 patients).PS,cerebral blood flow (CBF),cerebral blood volume (CBV) and mean transit time (MTT) on both sides of brains were measured.The relative PS(rPS),relative CBF (rCBF),relative CBV(rCBV) and relative MTT(rMTT) were obtained by calculating the ratio of the values of bilateral regions.The rPS between PSHT and PSNo-HT was compared with an exact Wilcoxon signed-rank test. The rCBF,rCBV,rMTT and the PS of the ischemic side between PSHr and PSNo-HT were compared with independent-sample t test.Meanwhile,Spearman rank correlation analysis was conducted to analyze the relationship between the CTP parameters and HT.ResultsThe PS value of ischemic side was (1.61±0.77) ml · min - 1 · 100 g-1 for the PSHT group,and the value was (0.91 ± 0.49) ml · min - 1 · 100 g- 1 for the PSNo-HT group.For the PSHT group,rPS,rCBF,rCBV,rMTT were 2.76 ±0.78,0.32 ±0.18,0.66 ±0.31,2.67 ±0.71,and for the PSNo-HT group,rPS,rCBF,rCBV,rMTT were 1.35 ±0.19,0.50±0.21,0.91 ±0.28,2.62 ± 1.31.Compared with PSNo-HT,PSHT had higher rPS and PS value,and there were significant statistical differences (U =0.000,t =3.070,P <0.01).But rCBF and rCBV values were lower in the PSHT group compared to the PSNo-HT group,and there were significant statistical differences (trCsF =2.343,trCBV =2.210,P < 0.05).There was no significant statistical difference in rMTT between the two groups(t =0.118,P > 0.05).Significant positive correlations were detected between the rPS and PS with HT(r=0.496,0.821,P <0.01).ConclusionsThe value of rPS is helpful in predicting HT in AIS.And it can be used as a predictor in determining clinical personalized treatment and thus reduce the incidence of adverse events.
7.Efficacy of radiotherapy for adult patients with Langerhans cell histiocytosis.
Ming-hui DUAN ; Xiao HAN ; Jian LI ; Bing HAN ; Wei ZHANG ; Tie-nan ZHU ; Jun-ling ZHUANG ; Dao-bin ZHOU
Chinese Journal of Hematology 2013;34(6):482-484
OBJECTIVETo analyze efficacy of radiotherapy for adult patients with Langerhans cell histiocytosis (LCH).
METHODSClinical features and efficacy of radiotherapy for biopsy-proven adult patient with LCH from January 2000 to October 2012 in our hospital were retrospectively analyzed.
RESULTSSeventeen (11 male and 6 female) adult LCH patients with a mean age of 31 (18-56) years old were treated by irradiation, all patients presented as single-system disease. The mean duration from diagnosis to irradiation was 8.3 (0-108) months. Although 12 of 17 patients (70.6%) had short-term response to radiotherapy, all patients but one (94.1%) progressed during long-term follow-up, the mean progression-free survival (PFS) was 14 (0-131) months. Of the progressed patients, one relapsed in situ, the remaining 15 patients progressed outside the irradiated region. Thirteen patients (76.5%) eventually progressed to multisystem disease.
CONCLUSIONThough radiotherapy for LCH in adults produced a high short-term response up to 70.6%, most of patients eventually progressed in situ or outside the irradiation region during long-term follow-up.
Adolescent ; Adult ; Disease Progression ; Disease-Free Survival ; Female ; Histiocytosis, Langerhans-Cell ; radiotherapy ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult
8.Association of polymorphism on HLA-DRB1*04 alleles with outcome of hepatitis B virus infection.
Ming-sheng SONG ; Hong-wei LI ; Huai-yan PENG ; Bing-nan DUAN ; Hui CHEN ; Ling-qing XU
Chinese Journal of Medical Genetics 2007;24(4):467-469
OBJECTIVETo investigate the relation between the alleles of HLA-DRB1*04 and outcome of HBV infection.
METHODSThe alleles of HLA-DRB1*04 were detected by polymerase chain reaction-sequence specific primer (PCR-SSP). The frequency of allele of HLA-DRB1*04 in four groups[106 asymptomatic HBsAg carriers (group ASC), 93 chronic hepatitis B patients (group CHB), 77 patients with hepatitis B cirrhosis and 102 cases of spontaneous recovery after HBV infection (control group)] were studied, and the frequency of that in different replication of HBV was also studied.
RESULTSThe frequency of allele of HLA-RB1*04 in groups ASC, CHB and hepatitis B cirrhosis was markedly higher than that of control group (25.94%, 26.34%, 27.92% respectively versus 14.22%, P< 0.01); the frequency of HLA-DRB1*0401 in groups ASC, CHB and hepatitis B cirrhosis was also higher than that of control group (20.91%, 24.49%, 22.09% respectively versus 8.62%, P< 0.05, P< 0.01,P< 0.05 respectively); the frequency of HLA-DRB1*0405 in groups ASC, CHB and hepatitis B cirrhosis was lower than that of control group (3.64%, 2.04%, 3.49% respectively versus 15.52%, P< 0.01, P< 0.01, P< 0.05 respectively ). There was no statistical significance in the allele frequency of HLA-DRB1*04 among groups ASC, CHB and hepatitis B cirrhosis (P> 0.05), and the same result was observed in different replication of HBV (P> 0.05).
CONCLUSIONHLA-DRB1*04 gene is one of the factors which determine the outcomes of HBV infection, while it has no influence on HBV replication.
Adolescent ; Adult ; Alleles ; Female ; Gene Frequency ; Genetic Predisposition to Disease ; genetics ; HLA-DR Antigens ; genetics ; HLA-DRB1 Chains ; Hepatitis B ; genetics ; pathology ; Humans ; Male ; Middle Aged ; Polymerase Chain Reaction ; Polymorphism, Genetic ; genetics ; Prognosis ; Young Adult
9.Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia.
Li JIAO ; Shu-Jie WANG ; Jun-Ling ZHUANG ; Yong-Qiang ZHAO ; Dao-Bin ZHOU ; Ying XU ; Bing HAN ; Wei ZHANG ; Ming-Hui DUAN ; Nong ZOU ; Tie-Nan ZHU ; Ti SHEN
Acta Academiae Medicinae Sinicae 2009;31(5):555-558
OBJECTIVETo compare the efficacy and adverse effects between arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL).
METHODSThe clinical data of 71 patients with newly diagnosed APL were retrospectively analyzed. Two groups were classified according to the induction regimens, namely ATO group (n = 41) and ATRA group (n = 30). The complete remission (CR) rate and the time to CR were compared between these two groups.
RESULTSThe CR rate was 97.5% in ATO group and 93.3% in ATRA group (P > 0.05). The median time to CR was 29 days (21-45 days) in ATO group, which was significantly shorter than 38.5 days (24-63 days) in ATRA group (P < 0.001). Retinoic acid syndrome occurred in 52.9% of patients treated with ATRA, which affected the further use of ATRA.
CONCLUSIONSBoth ATO and ATRA have high response rates for newly diagnosed patients with APL. Compared with ATRA, ATO induction therapy has shorter time to achieve CR and less adverse effects, and therefore may be the first-line therapy for APL.
Adolescent ; Adult ; Aged ; Arsenicals ; adverse effects ; therapeutic use ; Female ; Humans ; Leukemia, Promyelocytic, Acute ; drug therapy ; Male ; Middle Aged ; Oxides ; adverse effects ; therapeutic use ; Remission Induction ; Retrospective Studies ; Treatment Outcome ; Tretinoin ; adverse effects ; therapeutic use ; Young Adult
10.Posaconazole as primary prevention of fungal infection in intensive immunosuppressive therapy for severe aplastic anemia.
Miao CHEN ; Jun Ling ZHUANG ; Ming Hui DUAN ; Wei ZHANG ; Jian LI ; Tie Nan ZHU ; Hua Cong CAI ; Xin Xin CAO ; Jun FENG ; Chen YANG ; Yan ZHANG ; Lu ZHANG ; Dao Bin ZHOU ; Bing HAN
Chinese Journal of Hematology 2018;39(2):128-131
Objective: To Evaluate the efficacy and safety of posaconazole as primary prevention of invasive fungal disease (IFD) in patients with severe aplastic anemia (SAA) treated with anti-thymus/lymphocyte immunoglobulin (ATG/ALG) combined with cyclosporine intensive immunosuppressive therapy (IST). Methods: A retrospective analysis of clinical data of 58 SAA patients who received IST of anti-thymocyte immunoglobulin combining cyclosporine and antifungal prophylaxis during April 2013 to May 2017 in Peking Union Medical College Hospital was performed. The patients were divided into posaconazole prophylaxis group and the control group (itraconazole or fluconazole). The disease characteristics, IFD prevention effect and adverse drug reaction, curative effect and prognosis of the two groups were compared. Results: Posaconazole was used to prevent fungal infection in 20 patients. The other 38 patients were used as the control group. Retrospective analysis showed comparable characteristics (gender, age, disease severity, etiology, interval between the onset of disease to treatment, ATG/ALG type) of both groups. The incidence of IFD were 0 and 15.8% in posaconazole prophylaxis group and the control group, respectively (P=0.084). In the control group, there were 6 cases diagnosed as IFD. Of them, 2 were confirmed, 2 suspected and 2 not identified. Five of the 6 cases were pulmonary infection, 1 bloodstream infections. Of the 6 IFD cases, 5 were very severe aplastic anemia (VSAA). There was no obvious adverse reaction in posaconazole prophylaxis group. Conclusion: Posaconazole is safe and effective for primary prevention of fungal infection of SAA patients receiving IST, especially for the VSAA.
Anemia, Aplastic
;
Cyclosporine
;
Humans
;
Immunosuppressive Agents
;
Mycoses/prevention & control*
;
Primary Prevention
;
Retrospective Studies
;
Treatment Outcome
;
Triazoles/therapeutic use*